TY  - GEN
AU  - Romera Martínez, Irene
AU  - Avendaño-Solá, Cristina
AU  - Villegas Da Ros, Carolina
AU  - Bosch Llobet, Alba
AU  - García Erce, José Antonio
AU  - González Fraile, María Isabel
AU  - Guerra Domínguez, Luisa
AU  - Vicuña Andrés, Isabel
AU  - Anguita Velasco, Javier
AU  - González Rodríguez, Victoria Paz
AU  - Contreras, Enric
AU  - Urcelay Uranga, Sabin
AU  - Pajares Herraiz, Ángel Luis
AU  - Jimenez-Marco, Teresa
AU  - Ojea Pérez, Ana María
AU  - Arroyo Rodríguez, José Luis
AU  - Perez-Olmeda, Mayte
AU  - Ramos-Martínez, Antonio
AU  - Velasco-Iglesias, Ana
AU  - Bueno Cabrera, José Luis
AU  - Duarte, Rafael F
PY  - 2024
DO  - 10.1111/vox.13561
UR  - http://hdl.handle.net/20.500.12105/16731
AB  - Background and objectives: The efficacy of COVID-19 convalescent plasma (CP) associates with high titres of antibodies. ConPlas-19 clinical trial showed that CP reduces the risk of progression to severe COVID-19 at 28 days. Here, we aim to study...
LA  - eng
PB  - Wiley
KW  - anti-SARS-CoV-2
KW  - Convalescent plasma
KW  - COVID-19
KW  - Donors
KW  - Passive immunotherapy
TI  - Factors related to the development of high antibody titres against SARS-CoV-2 in convalescent plasma donors from the ConPlas-19 trial
TY  - research article
ER  -